DISEASE CATEGORY: Cancer INDICATION: Melanoma Promoting the expression of immune genes IFI16 and NLRC5 directly, or indirectly by inhibiting epigenetic protein PRMT5, could treat melanoma. In patients, high tumor expression of IFI16 or NLRC5 and...

The all-hands-on-deck COVID-19 response provides a glimpse of what’s possible when drug developers converge around solving a problem. One of the most important developments might be in preclinical research where consensus on harmonized models and...

Targeted delivery of antibacterial toxins University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...

A new understanding of amyloid precursor protein (APP) variants from researchers at Sanford Burnham Prebys Medical Discovery Institute and University of California San Diego could help explain why Alzheimer's disease candidates targeting the amyloid pathway...

Head of Global R&D Elias Zerhouni will retire from Sanofi (Euronext:SAN; NYSE:SNY), effective June 30. He has held the post since 2011. John Reed will succeed Zerhouni. This month, Reed stepped down as head of...

Roche (SIX:ROG; OTCQX:RHHBY) said John Reed, the head of its Pharma Research and Early Development unit, is leaving the company for "personal reasons" and returning to the U.S., effective April 2. William Pao, global head...

Sanford Burnham Prebys Medical Discovery Institute agreed to return $12.3 million to the state of Florida as the institute prepares to wind down operations at its Florida campus. Sanford Burnham first announced its plans to...

TECHNOLOGY: Nanoparticles; peptides Silicon-based nanoparticles linked to bacteria-targeting peptides could help deliver antibiotics to treat bacterial infections. Generation of the pathogen-specific nanoparticles involves screening a peptide library in vitro and in mouse-based bacteria binding assays...

INDICATION: Alzheimer's disease (AD) Patient sample and mouse studies suggest promoting the interaction of SORL1 with EPHA4 could help treat AD. In frontal cortical tissue samples from postmortem patients, levels of activated EPHA4 -- a...